Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
Emi Harada(National Institute of Biomedical Innovation, Health and Nutrition), Tetsuji Naka(National Institute of Biomedical Innovation, Health and Nutrition)
Cited by 61
Related Papers
The paradigm of IL-6: from basic science to medicine.
|Arthritis Research|2002|481
Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis
|Inflammatory Bowel Diseases|2012|230
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
|British Journal of Cancer|2016|135
SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases
|Gastroenterology Research and Practice|2010|118
Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer
|International Journal of Cancer|2017|66